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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYMultipotent humanmesenchymal stromal cells (hMSCs) harbor immunomodulatory properties that are therapeutically relevant. One of
themost clinically important populations of leukocytes is the interleukin-17A (IL-17A)-secreting T (Th17) lymphocytes. However, mech-
anisms of hMSC and Th17 cell interactions are incompletely resolved. We found that, along with Th1 responses, hMSCs strongly sup-
pressed Th17 responses and this required both IL-25—also known as IL-17E—as well as programmed death ligand-1 (PD-L1), a potent
cell surface ligand for tolerance induction. Knockdown of IL-25 expression in hMSCs abrogated Th17 suppression in vitro and in vivo.
However, IL-25 alone was insufficient to significantly suppress Th17 responses, which also required surface PD-L1 expression. Critically,
IL-25 upregulated PD-L1 surface expression through the signaling pathways of JNK and STAT3, with STAT3 found to constitutively
occupy the proximal region of the PD-L1 promoter. Our findings demonstrate the complexities of hMSC-mediated Th17 suppression,
and highlight the IL-25/STAT3/PD-L1 axis as a candidate therapeutic target.INTRODUCTION
Multipotent human mesenchymal stromal cells (hMSCs)
are somatic progenitors that can be isolated from bone
marrow (BM) (Friedenstein, 1976; Pittenger et al., 1999)
and many other sites, such as adipose tissue, umbilical
cord blood, and placenta (Erices et al., 2000; Yen et al.,
2005; Zuk et al., 2001). Previous studies have indicated
that hMSCs can differentiate into the paraxial mesodermal
lineages of osteoblasts, chondrocytes, and adipocytes, as
well as other non-mesodermal lineages, given the right
environmental cues (Dominici et al., 2006; Engler et al.,
2006). As such, hMSCs have been widely applied in many
clinical trials for regenerative medicine (Giordano et al.,
2007; Hare et al., 2012).Moreover, hMSCs have been found
to have strong immunomodulatory properties that have
tremendous therapeutic potential, as evidenced by the
numerous clinical trials for immune-related diseases using
these versatile progenitor cells (Gebler et al., 2012; Le Blanc
et al., 2008; Tan et al., 2012). The hMSCs modulate diverse
populations of leukocytes, with the best studied being that
toward T lymphocytes, suppressing T effector functions
(Bartholomew et al., 2002; Di Nicola et al., 2002; Uccelli392 Stem Cell Reports j Vol. 5 j 392–404 j September 8, 2015 j ª2015 The Aet al., 2008). The molecular basis appears to involve both
paracrine factors—especially in the human system—
including tumor growth factor-b (TGF-b), indoleamine
2,3-dioxygenase (IDO), and prostaglandin E2 (PGE2), as
well as cell surface molecules that engage leukocyte surface
receptors (Uccelli et al., 2008; Chen et al., 2011). The
hMSCs also influence the diversity of CD4 T helper (Th)
subset phenotypes, potently skewing Th1 into Th2 cell re-
sponses (Aggarwal and Pittenger, 2005; Aksu et al., 2008)
and potentiating induction of regulatory T cells (Tregs),
an immunomodulatory population of T cells (Chang
et al., 2006; Maccario et al., 2005; Selmani et al., 2008).
One population of T lymphocytes that has moved
into greater prominence are interleukin (IL)-17A-secreting
Tcells (Dong, 2008). Known also as Th17 cells, this T helper
cell subpopulation is important in mediating host re-
sponses toward microbial infections, as well as partici-
pating in the pathogenesis of many autoimmune and
chronic inflammatory diseases that had been long believed
to be caused by Th1 cells (Miossec and Kolls, 2012). While
some studies have shown that hMSCs attenuate Th17-
mediated immunity (Ghannam et al., 2010; Gonza´lez
et al., 2009; Xu et al., 2012), others have found that hMSCsuthors
Figure 1. Multipotent Human Mesenchymal Stromal Cells
(hMSCs) Suppress Th17 Responses
(A–D) Human peripheral blood CD3+ leukocytes (PBLs) (A, repre-
sentative data; B, pooled data of 17 PBL donors co-cultured with all
three hMSC donors) or CD3+ CD4 T cells (C, representative data;
D, pooled data of 11 PBL donors co-cultured with all three hMSC
donors) were co-cultured without (left) or with (right) hMSCs
ex vivo, followed by PMA/ionomycin stimulation for 6 hr.
(E–H) IL-17A production in ex-vivo-cultured CD3+ T cells was
assessed by intracellular staining. IL-17A and IFN-g production in
Stem Cellactually enhance Th17 responses (Darlington et al., 2010;
Tso et al., 2010). These discrepant reports are likely due to
an incomplete understanding currently of themechanisms
involved in hMSC-Th17 lymphocyte interactions, which
have important implications in the clinical use of hMSCs
given the role of Th17 cells in human diseases (Korn
et al., 2009). We therefore set out to examine the nature
of hMSC-Th17 interactions and elucidate the mechanisms
involved. We found that hMSCs suppress Th17 responses
through both paracrine and cell-cell contact mechanisms,
involving IL-25—also known as IL17E—as well as PD-L1,
a ligand of the PD-1 family. Our data demonstrate that
hMSCs constitutively secrete IL-25 to upregulate the cell
surface expression of PD-L1 through JNK and STAT3, with
STAT3 involved in the transcriptional control of PD-L1.RESULTS
hMSCs Inhibit Th17 Responses
Since there have been discrepant reports on MSC-Th17
interactions, we first set out to answer whether hMSCs
enhance or suppress Th17 cell expansion. To determine
this, we used placenta-derived hMSCs thatwehave demon-
strated previously to be trilineage multipotent progenitors
and immunomodulatory, similar to BMMSCs (Yen et al.,
2005, 2013; Chang et al., 2006). We then co-cultured these
hMSCs with human peripheral blood leukocytes (PBLs) or
purified CD4 T cells in steady state for 3 days. Approxi-
mately 1%–3% of non-primed T cells became IL-17A
producers after phorbol 12-myristate 13-acetate (PMA)/
ionomycin treatment for 6 hr, and we found that, when
hMSCs were present, the frequency of IL-17A-expressing
T cells was strongly decreased by 60%–65% in PBLs (Fig-
ure 1A, representative data; Figure 1B, pooled data) or
CD4 T cells (Figure 1C, representative data; Figure 1D,
pooled data). To further confirm this phenomenon, weCD3+ PBLs (E, representative data; F, pooled data) or CD3+ CD4
T cells (G, representative data; H, pooled data) without and with
co-culture of hMSCs was analyzed by flow cytometry. Representa-
tive intracellular staining is shown for IL-17A+ IFN-g- CD3+ T cells
(R3 region) and IL-17A+IFN-g+ (R5 region) CD3+ T cells, and pooled
data from PBLs (n = 4) or CD4 T cells (n = 4) co-cultured with two
hMSC donors (donors A and B) are provided in (F) and (H),
respectively. Gray bars represent the percentages of IL-17A+
IFN-g- CD3+ T cells, whereas white bars represent the percentages
of IL-17A+IFN-g+ T cells.
(I and J) IL-22 production in four donors of CD3+ CD4 T cells
(I, representative data; J, pooled data) without and with co-culture
of two donors of hMSCs (donors A and B) was assessed by
intracellular staining. Cell percentages are denoted in the dotplot
quadrant of interest. Data are shown as mean ± SD. *p < 0.05,
**p < 0.01.
Reports j Vol. 5 j 392–404 j September 8, 2015 j ª2015 The Authors 393
performed in vitro stimulation of PBLs or T cells with anti-
CD3/CD28 beads plus ionomycin to activate the Th17
effector phenotype (Santarlasci et al., 2012). We found
that the frequency of in-vitro-expanded IL-17A-expressing
PBLs (Figure S1A, representative data; Figure S1B, pooled
data) and T cells (Figure S1C, representative data; Fig-
ure S1D, pooled data) was significantly reduced, as well
when hMSCs were present.
It is known that the lineages of Tregs and Th17 are linked,
with one lineage chosen over another to maintain immune
homeostasis (Weaver and Hatton, 2009). Concomitantly,
we found that, after co-culture with hMSCs, the frequency
of FOXP3-expressing natural Tregs in PBLs and CD4
cells was increased (Figures S1E and S1F). hMSCs not only
suppress IL-17A cells, but also prominently suppress IL-
17A/IFN-g double producer cells, which are the dominant
subtype of Th17 cells at inflammatory sites (Annunziato
et al., 2007; Zielinski et al., 2012). Previous reports have
shown that hMSCs strongly suppress IFN-g production—a
prototypical Th1 cytokine—in PBLs and T cells (Aksu et al.,
2008; Aggarwal and Pittenger, 2005), and we also found
this to be true (Figures 1E and 1G, respectively). Addition-
ally, we found that hMSCs substantially suppressed IFN-g/
IL-17A-expressing Tcells (for PBLs: Figure 1E, representative
data and Figure 1F, pooled data; for CD4 cells: Figure 1G,
representative data and Figure 1H, pooled data). Th17 cells
also are known to produce IL-22 (Dong, 2008), and co-cul-
ture of CD4 T cells with hMSCs also significantly decreased
IL-22 production (Figure 1I, representative data; Figure 1J,
pooled data). These results, therefore, demonstrate that
hMSCs effectively suppress Th17 responses.
hMSCs Constitutively Express IL-25
In the human system, MSC-T cell interactions have pre-
dominantly involved paracrine factors (Kim et al., 2013);
therefore, to identify possible candidate secreted factors
capable of suppressing Th17 responses, we performed
mass spectrometry (MS) analysis on hMSC-conditioned
medium. Surprisingly, MS/MS studies revealed that IL-25,
also known as IL17E and a potent suppressor of Th17
responses (Kleinschek et al., 2007; Zaph et al., 2008), was
highly secreted by hMSCs. To reconfirm MS/MS results,
we examined for transcripts of IL-25 in various sources of
hMSCs against other stromal cell types, such as fibroblasts.
IL-25 mRNA could be detected in hMSCs, but not in
human fibroblast cell lines MRC-5 or WS-1 (Figure 2A).
We also detected the expression of IL-25 mRNA in three
different donors each of placenta-derived hMSCs and hu-
man BMMSCs (Figure 2B), suggesting the reliability of
IL-25 expression across the different sources of hMSCs. To
ascertain protein production of IL-25, we performed west-
ern blot for overall protein production (Figure 2C) and
intracellular flow cytometric analysis to detect IL-25 (Fig-394 Stem Cell Reports j Vol. 5 j 392–404 j September 8, 2015 j ª2015 The Aure 2D), and we detected protein expression in both assays.
Moreover, we found that hMSCs expressed IL-25 protein
that could be detected in a secreted form in the conditioned
medium, as detected by ELISA (Figure 2E). These findings
indicate that hMSCs constitutively produce IL-25.
Silencing of hMSC-Derived IL-25 Reverses Suppression
of Th17Responses InVitro and InVivo, but Exogenous
IL-25Alone Is Not Sufficient to Repress Th17Responses
To assess whether hMSC-secreted IL-25 is involved in
suppressing Th17 responses, we silenced IL-25 (siIL-25)
expression in hMSCs by RNA interference. After confirm-
ing the efficiency of knockdown (Figures S2A and S2B),
we found that silencing of IL-25 secretion with small inter-
fering RNA (siRNA) specific for the gene in hMSCs almost
completely reversed the suppressive effects toward Th17
cells compared with control silenced hMSCs (siCtrl) (Fig-
ure 3A). An average decrease of 35% in IL-17A-expressing
T cells was seen with co-culture of siCtrl hMSCs; this
was completely abrogated when siIL-25 hMSCs were
applied (Figure 3B). A similar trend was seen when siCtrl
or siIL-25 hMSCs were co-cultured with purified CD4 lym-
phocytes (Figure 3C). Th17 lymphocytes were decreased to
an average of 52%of baselinewhen siCtrl hMSCswere used
in the co-culture, compared to 87% when siIL-25 hMSCs
were applied (Figure 3D). We further confirmed the capac-
ity of hMSC-derived IL-25 for Th17 suppression under
in vivo inflammatory conditions by adoptive transfer of
either siCtrl hMSCs or siIL-25 hMSCs into lipopolysaccha-
ride (LPS)-treated C57BL/6J mice (Figure 3E). We found
that in vivo transfer of siCtrl hMSCs suppressed the popu-
lation of IL-17A-expressing CD4 T cells in the spleen,
whereas siIL-25 hMSCs failed to achieve that (Figures 3F
and 3G). With transfer of siCtrl hMSCs, IL-17A-expressing
T cells were decreased to an average of 41% of baseline, but
transfer of siIL-25 hMSCs nearly completely abrogated
these effects with IL-17A-expressing T cells back at an
average level of 98% (Figure 3H). These data demonstrate
that IL-25 secretion by hMSCs is involved in suppressing
Th17 responses in vitro and in vivo.
To further ascertain the role of IL-25 in suppressing Th17
responses, we treated CD4 Tcells with recombinant human
IL-25 (rhIL-25) for 18 hr prior to PMA/ionomycin stimula-
tion and examined for levels of IL-17A in CD4 cells. To our
surprise, we found that the addition of IL-25 singly to CD4
T cells failed to suppress Th17 responses to a significant
extent (Figure 4A, representative data; Figure 4B, pooled
data). Moreover, when hMSCs were separated from CD4
T cells by Transwell membrane, suppressive effects toward
Th17 cells in CD4 cells were lost (Figure 4C, representative
data; Figure 4D pooled data). This indicates that a mem-
brane-bound factor is likely involved in IL-25-mediated
effects.uthors
Figure 2. hMSCs Constitutively Express
IL-25
(A–D) Gene expression of IL-25 in placenta-
derived hMSCs and fibroblast cell lines
(MRC-5 and WS-1) (A), as well as three do-
nors each of placental (left) and bone
marrow (BM; right) hMSCs (B), was assessed
by RT-PCR. Protein expression of IL-25 was
determined by western blotting (C, K562
cell line and indicated amounts of recom-
binant human IL-25 [rhIL-25] as positive
controls; tubulin as internal control) and
intracellular staining for flow cytometric
analysis (D; left, placental hMSC donor A;
right, BM hMSC donor A).
(E) Filled histograms represent isotype
control; unfilled histograms represent IL-25
antibody staining, with pooled data (three
donors each of placental and BM hMSCs).
Ctrl, isotype control; MFI, mean fluores-
cence intensity; A.U., arbitrary units.
(F) Secreted IL-25 by placental hMSCs
(donor C, black bar), BM hMSCs (donor B,
gray bar), MRC-5 (striped bar), or WS-1
(white bar) was assessed by collected
conditioned medium of each cell type and
analyzed by ELISA. Data are shown as mean
± SD of technical triplicates.hMSC-Secreted IL-25 Suppresses Th17 Responses by
Upregulating Surface Expression of PD-L1
It has been reported that PD-L1 ligand, which is constitu-
tively expressed on hMSC cell surfaces (Chang et al.,
2006; Stagg et al., 2006), is a strong inhibitor of IL-17A pro-
duction in human T cells (Brown et al., 2003; Hirahara
et al., 2012). Hence, we considered the possibility that
hMSC-secreted IL-25 effects on Th17 responses may be
mediated through interacting with this MSC-cell-surface
molecule. To ascertain previous reports of the suppressive
effects of PD-L1 on Th17 cells, we performed knockdown
of PD-L1 expression on hMSCs with siPD-L1 (Figure 5A).
In line with previous reports, we found that PD-L1 knock-
down in hMSCs reversed the suppression of Th17 cells (Fig-
ures 5B and 5C), but to a significantly lesser degree than
that with siIL-25 (Figure 5D). To assess the role of PD-L1
in IL-25-dependent suppression of Th17 responses, we
asked whether IL-25 is involved in the expression of PD-
L1 on hMSCs. We found that, when IL-25 was silenced inStem CellhMSCs, surface expression of PD-L1 was strongly reduced,
to a degree similar to knockdown with siRNA specific for
itself (Figure 5E, representative data; Figure 5F, pooled
data of siIL-25 versus siPD-L1), suggesting that IL-25 may
induce PD-L1 expression. The receptor for IL-25 is IL-25R
(Lee et al., 2001), and we searched for expression of
IL-25R in hMSCs; western blotting revealed that hMSCs
constitutively express this receptor (Figure S3A). When
IL-25R expression was silenced on hMSCs with siIL-25R
(Figure S3B), we found that hMSC-mediated suppression
of Th17 response was significantly abrogated (Figures S3C
and S3D). Thus, hMSC-secreted IL-25 requires interaction
with its receptor IL-25R on hMSCs to lead to the suppres-
sion of Th17 responses.
To further ascertain interactions of IL-25 on PD-L1
expression, we added rhIL-25 directly to hMSCs and as-
sayed for further upregulation of PD-L1. We found that
exogenous rhIL-25 can further upregulate surface expres-
sion of PD-L1 on hMSCs, but not to a significant extentReports j Vol. 5 j 392–404 j September 8, 2015 j ª2015 The Authors 395
Figure 3. IL-25 Silencing in hMSCs
Reverses Th17 Responses In Vitro and
In Vivo
(A–D) Freshly isolated human PBLs (A) or
CD4 T cells (C) were co-cultured without
(left) or with either siCtrl hMSCs (middle)
or siIL-25 hMSCs (right) for 3 days, followed
by PMA/ionomycin stimulation for 6 hr.
IL-17A production in CD3+ T cells was as-
sessed by intracellular staining. Numbers in
the top right quadrants represent the per-
centages of IL-17A-producing CD3+ T cells.
Pooled data from PBLs (n = 3) or CD4 T cells
(n = 3) and two hMSC donors (donors A and
B) are provided in (B) and (D), respectively.
Data are shown as mean ± SD. *p < 0.05,
**p < 0.01.
(E) Experimental strategy for establishing
in vivo inflammatory conditions in wild-
type C57BL/6J mice with expansion of Th17
cells and adoptive transfer of hMSCs is
shown.
(F) On day 3 after LPS (100 mg/mouse)
challenge, IL-17A production in activated
CD4 T cells in splenocytes from control mice,
PBS-treated mice, siCtrl-hMSC-treated mice,
or siIL-25-hMSC-treated mice was assessed
by intracellular staining.
(G and H) Calculated (G) and relative (H)
mean percentage of IL-17A-expressing
CD4 T cells among control mice, PBS-treated
mice, siCtrl-hMSC-treated mice, or siIL-
25-hMSC-treated mice (n = 6). Data are
shown as mean ± SD. *p < 0.05, **p < 0.01,
***p < 0.005.(Figure 5G), which may be due to the fact that PD-L1 is
constitutively expressed at a high level on hMSCs and
thereby masking further effects of rhIL-25. Thus, to clarify
the significance of IL-25 on PD-L1 expression, we used hu-
man primary monocytes from PBLs since these cells are
known to respond to IL-25 as well as express low levels of
PD-L1 at baseline (Caruso et al., 2009b). We found that,
when human PBLs were treated with rhIL-25, PD-L1
expression was dramatically and significantly increased in
monocytes in a dose-dependent manner (Figure 5H, repre-
sentative data; Figure 5I, pooled data). Thus, these findings
demonstrate that IL-25 is involved in regulation of PD-L1
surface expression in both hMSCs and human monocytes.396 Stem Cell Reports j Vol. 5 j 392–404 j September 8, 2015 j ª2015 The AIL-25-Induced Upregulation of PD-L1 Is Mediated
through JNK and STAT3, with STAT3 Involved in
Transcriptional Control of PD-L1
We next sought to explore the signaling pathways by
which IL-25 mediates expression of PD-L1. We first used
monocytes from human PBLs, in which the expression of
PD-L1 is inducible rather than constitutive, to answer
this question. In human primary monocytes, WP1066, a
STAT3 inhibitor, or SP600125, a JNK inhibitor, substan-
tially abolished IL-25-mediated induction of PD-L1 (Fig-
ure 6A, representative data; Figure 6B, pooled data). In
contrast, PD98059, a MEK1/2 inhibitor, showed minimal
effect, while LY294002, a PI3K inhibitor, and Akt inhibitoruthors
Figure 4. Exogenous IL-25 Alone Is
Insufficient to Significantly Suppress
Th17 Responses, with Cell Contact
Required as well for hMSC-Mediated Inhi-
bition of Th17 Responses
(A) Human CD4 T cells were treated with
indicated doses of rhIL-25 for 18 hr, fol-
lowed by PMA/ionomycin stimulation for
6 hr. IL-17A production in CD3+ T cells
was assessed by intracellular staining.
Numbers in the top right quadrants repre-
sent the percentages of IL-17A-producing
CD3+ T cells.
(B) Pooled data of five PBL donors are
shown.
(C) Human CD4 T cells (n = 4) were co-
cultured without or with hMSCs (two donors,
B and C) in the absence or presence of
transwell barriers.
(D) Pooled data from healthy donors are
shown. Data are shown as mean ± SD. **p <
0.01; n.s., not significant.III only partially affected IL-25-induced expression of PD-
L1 (Figures S4A and S4B). In hMSCs, which constitutively
express high levels of PD-L1, we also found that inhibition
of STAT3 with WP1066 (Figure 6C) or JNK with SP600125
(Figure 6D) strongly reduced PD-L1 expression.
Since STAT3 is also a transcription factor, we reasoned
that this molecule may not only be involved in the signal
pathway of IL-25-mediated PD-L1 expression, but also
play a role in transcriptional control of PD-L1. To answer
this question, we first analyzed the promoter of human
PD-L1 gene between nucleotide 700 and nucleotide +1
for putative STAT3-binding elements. Based on software
prediction, three putative GAS elements (STAT3-binding
sites) between 595 and 116 bp upstream of the transcrip-
tional start site were found (Figure 6E), raising the possibil-
ity that STAT3 may directly bind to the promoter of PD-L1.
To test this possibility, we performed chromatin immuno-
precipitation (ChIP) to determine whether STAT3 binds to
the PD-L1 promoter in hMSCs, and we found that STAT3
was constitutively recruited to the GAS elements on the
PD-L1 promoter (Figure 6F). Thus, our data demonstrate
that, in hMSCs, IL-25 mediates cell surface expression of
PD-L1 through JNK and STAT3, with the latter involved in
the transcriptional control of PD-L1 (Figure 6G).DISCUSSION
hMSCs are known to be broadly immunomodulatory and
these effects are therapeutically relevant (Caplan and Cor-
rea, 2011; Le Blanc and Mougiakakos, 2012; Uccelli et al.,Stem Cell2008). Th17 cells are now known to be involved in the
pathogenesis of a number of autoimmune and chronic
inflammatory diseases (Miossec and Kolls, 2012); hMSC in-
teractions with this important population of leukocytes,
however, have been shown to be discrepant (Darlington
et al., 2010; Ghannam et al., 2010; Gonza´lez et al., 2009;
Tso et al., 2010; Xu et al., 2012). Our data reveal that the
effects of hMSCs on Th17 cells are suppressive and require
both a paracrine factor, IL-25, as well as a cell surface mole-
cule, PD-L1. Moreover, expression of PD-L1 in hMSCs is
linked to IL-25 through IL-25R and further downstream
through JNK and STAT3, the latter of which is involved
in the transcriptional control of PD-L1. Th17 cells have
been recognized as a contributor to transplant rejection
through unknown mechanisms (Antonysamy et al.,
1999; Faust et al., 2009). Our data may shed some light
on the mechanisms behind the strong therapeutic effects
of hMSC therapy on related diseases (Bassi et al., 2012;
Sun et al., 2009; Zhou et al., 2011) and implicate a role
for IL-25 agonists in ameliorating autoimmune/inflamma-
tory diseases as well as transplant rejection.
IL-25 (IL-17E) is a member of the IL-17 family (Iwakura
et al., 2011). However, unlike IL-17A or F, the better-known
members of this IL family that have direct roles in autoim-
muneand chronic inflammatory diseases, IL-25 actually ap-
pears to protect against IL-17A/Th17 andTh1 states (Caruso
et al., 2009a). IL-25-deficientmice, inaddition topromoting
Th1 responses, have a higher amount of IL-17A-expressing
T cells and IFN-g-expressing T cells in Th17-mediated
experimental autoimmune encephalomyelitis (EAE), a
model of human multiple sclerosis (Kleinschek et al.,Reports j Vol. 5 j 392–404 j September 8, 2015 j ª2015 The Authors 397
Figure 5. IL-25 Induces PD-L1 Surface Expression on hMSCs and Human Monocytes
(A) PD-L1 in siCtrl MSCs (left) and siPD-L1 MSCs (right) was analyzed by surface staining.
(B) Freshly isolated human PBLs were co-cultured without (left) or with siCtrl MSCs (middle) or siPD-L1 MSCs (right) for 3 days, followed by
PMA/ionomycin stimulation for 6 hr. IL-17A production in CD3+ T cells was assessed by intracellular staining. Representative data are
shown with numbers in the top right quadrants representing the percentages of IL-17A-producing CD3+ T cells.
(C) Pooled data from PBLs (n = 4) and two hMSC donors (donors A and B) are shown.
(legend continued on next page)
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Figure 6. IL-25-Mediated PD-L1 Expres-
sion in Human Monocytes and hMSCs Is
Mediated through JNK and STAT3, with
STAT3 Involved in Transcriptional Control
of PD-L1
(A) Human PBLs were pretreated with in-
hibitors of STAT3 (WP1066; 2.5 mM), JNK
(SP600125; 25 mM), or MEK1 (PD98059;
20 mM) prior to 100 ng/ml rhIL-25 for 18 hr,
with subsequent flow cytometric analysis for
PD-L1 surface expression on monocytes,
gated using FSC and SSC. Filled histograms
represent isotype control; unfilled histo-
grams represent PD-L1 antibody staining.
(B–D) Pooled data (three donors) are shown
(B) with bars representing MFI. hMSCs
were treated with inhibitors of STAT3
(C; WP1066, 2.5 mM) and JNK (D; SP600125,
25 mM) for 6 hr, and subsequently assessed
by flow cytometric analysis for PD-L1
surface expression. Pooled data (all three
donors) for each respective inhibitor are
provided (left charts) with bars repre-
senting MFI.
(E) Putative GAS elements (STAT-binding
sites) in the proximal promoter region
of human PD-L1 gene (700 bp region
upstream from the transcription start site),
as determined with TFSearch web-based
software.
(F) Binding of STAT3 or IgG (negative con-
trol) in hMSCs was analyzed by chromatin
immunoprecipitation (ChIP) with promoter-specific primers for region 1 and region 2. The input samples (positive control) represent 1%
starting chromatin.
(G) Schematic shows a model of hMSC-mediated suppression of Th17 responses involving the IL-25/STAT3/PD-L1 axis.2007). Interestingly, accumulating data demonstrate that
IL-25 has another role in the immune systemby promoting
Th2 responses, preventing helminth infections (Fallon
et al., 2006) as well as eosinophilic airway inflammation
(Kim et al., 2002). To date, reported sources of IL-25 include
immune cells, such as T cells, macrophages, monocyte-
derived dendritic cells, mast cells, eosinophils, and baso-
phils, as well as non-immune cells, such as epithelial and(D) Folds of reversed phenotypes of siIL-25 and siPD-L1 are shown.
(E) PD-L1 expression on siCtrl hMSCs (left) and siIL-25 hMSCs (right)
isotype control; unfilled histograms represent PD-L1 antibody stainin
(F) Pooled data of PD-L1 expression (indicated by fold change in MFI)
PD-L1 expression levels were compared between hMSCs silenced for t
(G) hMSCs were treated with the indicated doses of rhIL-25 for 18 hr an
Pooled data (all three donors) are shown in chart to the right with b
(H) Human PBLs were treated with the indicated doses of rhIL-25 for
gated using FSC and SSC, by flow cytometric analysis.
(I) Pooled data (ten PBL donors) are shown with bars representing M
Stem Cellendothelial cells (Monteleone et al., 2010). We found IL-
25 to be highly and constitutively expressed by diverse
sources of hMSCs, but not fibroblasts. Moreover, our data
show that IL-25 is directly responsible for hMSC suppres-
sion of allogeneic Th17 responses, including decreasing
the highly pathogenic IL-17A/IFN-g+ cells, further demon-
strating that IL-25 is broadly protective against Th17 and
Th1 responses. It is interesting to speculate on otherwas assessed by cell surface staining. Filled histograms represent
g.
on siIL-25 hMSCs and siPD-L1 hMSCs (all three donors) are shown.
he target gene (IL-25 or PD-L1) and the respective siCtrl.
d assessed for cell surface PD-L1 expression by cell surface staining.
ars representing MFI.
18 hr and assessed for cell surface PD-L1 expression on monocytes,
FI. *p < 0.05, **p < 0.01; n.s., not significant.
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possible biological roles of IL-25 in hMSCs given its
high constitutive expression. Further studies are ongoing
to evaluate whether this cytokine plays a role in hMSC pro-
liferation and/or differentiation.
One of the striking findings of this study is that IL-25
directly upregulates the surface molecule PD-L1 in
both leukocyte—monocytes—and non-leukocyte popula-
tions—hMSCs. PD-L1 is strongly immunosuppressive, be-
ing an inhibitor of autologous T cell activation in several
autoimmune diseases (Keir et al., 2008), and blockade of
its receptor, PD-1,onTcells canbevery effectiveagainst can-
cer immunosuppression, as recently demonstrated (Topa-
lian et al., 2012). Recently, a report showed that mouse
MSCs suppress Th17 responses through this pathway
(Luz-Crawford et al., 2012). However, data in this report
showed that blockage of the PD-L1/PD-1 pathway only
partially reversed mouse MSC suppression of Th17 re-
sponses, implicating other factors in this process. Our data
also demonstrate that silencing of PD-L1 results in partial
reversal of hMSC suppression of Th17 responses, while
silencing of IL-25 results in a significantly higher andnearly
complete reversal of hMSC-mediated Th17 suppression
(Figure 5D). In addition, the degree of knockdown of PD-
L1 expression was similar whether the siRNA specific for
IL-25 or PD-L1was used (Figure 5F).Moreover, we found ev-
idence that IL-25 can directly affect the transcription of PD-
L1 in both hMSCs and human leukocytes through STAT3,
whichhelps to resolve thequestionof PD-L1 transcriptional
control (Sumpter and Thomson, 2011; Wo¨lfle et al., 2011).
Critically,mouseMSCsdonot express PD-L1 in steady state,
whereas hMSCs constitutively express a high level of PD-L1
(Stagg et al., 2006). It is important to note that while data
from mouse systems are clearly important, in MSC immu-
nobiology, at times the results frommouse and human sys-
temshave been conflicting (Eliopoulos et al., 2005; Le Blanc
et al., 2008), aswas the casewithPD-L1expression.Basedon
the clinical response to hMSC therapy on various immune-
related diseases, it appears that hMSCs exert strong immu-
nomodulatory effects (Le Blanc and Mougiakakos, 2012),
which is not always evident withmouse studies (Eliopoulos
et al., 2005). Thus, to elucidate mechanisms involved in
hMSC therapeutic applications, in vitro studies using
hMSCs are still critical to conduct.
In summary, our findings demonstrate that hMSCs
suppress Th17 responses, which require both the secreted
factor IL-25 and IL-25-mediated upregulation of surface
PD-L1. The downstream signaling pathways of JNK and
STAT3 are involved in IL-25 regulation of PD-L1, with
STAT3 implicated in the transcriptional control of PD-L1.
In addition to the known roles of Th17 cells in autoim-
mune and chronic inflammatory diseases, recent studies
have shown the importance of Th17 cells in enhancing
the efficacy of checkpoint immunotherapy (Lutz et al.,400 Stem Cell Reports j Vol. 5 j 392–404 j September 8, 2015 j ª2015 The A2014). Modulation of IL-25, therefore, may have strong
clinical implications since this cytokine can modulate
PD-L1/PD-1 interactions and Th17 cells as well. Our find-
ings provide a better understanding of the crosstalk
between hMSCs and Th17 cells, as well as highlight the
IL-25/STAT3/PD-L1 axis as a candidate therapeutic target
for relevant diseases.EXPERIMENTAL PROCEDURES
Cell Culture
The hMSCs from BM and placenta were isolated and expanded
according to previously published protocols (Pittenger et al.,
1999; Yen et al., 2005). Briefly, placenta MSCs were isolated
from term human placentas (38- to 40-week gestation; three do-
nors designated A, B, and C) obtained with informed consent as
approved by the institutional review board. Placental tissue was
mechanically and enzymatically digested (0.25% trypsin-EDTA;
Gibco, Invitrogen) and cultured in DMEM-low glucose (Gibco,
Invitrogen), 10% fetal bovine serum (FBS; HyClone), 2 mM
L-glutamine (Gibco, Invitrogen), and 100 U/ml penicillin-strep-
tomycin (Gibco, Invitrogen). BMMSCs were obtained commer-
cially (Cambrex, two donors designated A and B; and Promocell,
one donor designated C). All hMSCs used were placental-derived
unless otherwise indicated. Human PBLs were isolated from the
buffy coat of healthy donor blood samples (Taiwan Blood Ser-
vices Foundation, Taipei Blood Center), obtained with informed
consent approved according to the procedures of the institu-
tional review board, and cultured as previously reported (Chang
et al., 2006; Yen et al., 2013). CD4 T cells were purified from PBL
using human CD4 MicroBeads (Miltenyi Biotec) according to the
manufacturer’s protocols. Purity was assessed by flow cytometric
analysis (>98% positive for CD4). Human fibroblast cell lines
MRC-5 and WS-1 were obtained from American Type Culture
Collection (ATCC) and cultured according to the suggested
protocols.MSC-Leukocyte Co-culture Experiments
The hMSCs were plated at 3.53 104 cells per well in six-well plates
and incubated at 37C for 24 hr prior to co-culture with human
PBL or CD4 cells. For co-cultures, 13 105 human PBL or CD4 cells
were added to hMSC-containingwells without or with stimulation
by magnetic anti-CD3/CD28-coated Dynabeads (Gibco, Invitro-
gen), according to the manufacturer’s instructions. After 3 days,
cells were stimulated by PMA (50 ng/ml; Sigma-Aldrich) plus ion-
omycin (1 mg/ml; Sigma-Aldrich) in the presence of monensin
(eBioscience) for 6 hr, followed by assessment of IL-17A expression
in Tcells using intracellular staining. For transwell cultures, human
PBL or CD4 cells were plated in the upper compartment of trans-
well plates (0.4-mm pore size; BD Falcon), while hMSCs were
plated in the lower compartment. Human recombinant IL-25
(rhIL-25; PeproTech) and various inhibitors (WP1066/InSolution
STAT3 inhibitor III and Akt inhibitor III from Millipore;
SP600125 JNK inhibitor and LY294002 PI3 kinase inhibitor from
Cell Signaling Technology; and PD98059/MEK1/2 inhibitor from
Cell Signaling Technology) were added to various experiments atuthors
the indicated doses after establishing toxicity profiles for mono-
cytes and hMSCs.Flow Cytometry
Cells were stained with antibodies as indicated: anti-human IL-
25-PE (R&D Systems, IC1258P), mouse IgG1 isotype control-PE
(R&D Systems, IC002P), anti-human CD3-PE/Cy5 (BioLegend,
300310), anti-human CD4-PE (BioLegend, 357404), anti-human
IL-17A-PE (eBioscience, 12-7179), anti-human IFN-g-FITC (Bio-
Legend, 502506), anti-human IL-22-PE (eBioscience, 12-7229),
anti-human FOXP3-Alexa Fluor 488 (BD Pharmingen, 561181),
anti-human CD274 (B1-H1)-PE (eBioscience, 12-5983), mouse
IgG1 isotype control-PE (eBioscience, 12-4714), anti-human IL-
25R-PE (R&D Systems, FAB1207P), mouse IgG2b isotype control-
PE (R&D Systems, IC0041P), anti-mouse CD4-APC (eBioscience,
17-0041), anti-mouse CD3e-PE/Cy5 (eBioscience, 15-0031), and
anti-mouse/rat IL-17A-PE (eBioscience, 12-7177). Data were
collected on BD FACSCalibur (BD Biosciences) instruments and
analyzed with Cell Quest Pro software (BD Biosciences).
MS
MS/MS experiments were performed as previously reported
(Chang et al., 2010). Briefly, MS/MS was performed with an
LTQ-Fourier transform (FT) ion cyclotron resonance (ICR) mass
spectrometer (ThermoElectron) equippedwith a nanoelectrospray
ion source (New Objective), an Agilent 1100 series binary high-
performance liquid chromatography (HPLC) pump (Agilent Tech-
nologies), and a Famos autosampler (LC Packings). A minimum
threshold of 1,000 counts was used as the cutoff for MS/MS
sequential isolation by the LTQ, with singly charged ions rejected
for MS/MS sequencing.
RT-PCR
Total RNA was prepared from cells using TRIzol reagent (Gibco,
Invitrogen) according to the manufacturer’s instructions. The
first-strand cDNA was synthesized from the RNA using Improm-
II reverse transcriptase (Promega). For PCR, cDNA was subjected
to PCR using the following primer sets: IL-25, forward 50-TTCCTA
CAGGTGGTTGCATTC-30, reverse 50-CGCCTGTAGAAGACAGTC
TGG-30 (Furuta et al., 2011); b-actin, forward 50-TGGCACCAC AC
CTTCTACAATGAGC-30, reverse 50-GCACAGCTTCTCCTTAATGT
CACGC 30.
ELISA
The human IL-25 ELISA kit was obtained from PeproTech and
performed according to the manufacturer’s instructions. The
detection range was 0–2,000 pg/ml.
RNA Interference
Human IL-25, IL-25R, or PD-L1 expression in hMSCs was silenced
using Stealth RNA interference (RNAi) duplex oligonucleotides
(Gibco, Invitrogen) according to the manufacturer’s instructions,
withnon-target siRNA (mediumGCduplex) used as control. Trans-
fection of RNAi was done using Lipofectamine RNAiMAX (Gibco,
Invitrogen) according to the manufacturer’s instructions. Knock-
down efficiency was confirmed by flow cytometry.Stem CellhMSC Adoptive Transfer
All animal work was performed in accordance with protocols
approved by the Institutional Animal Care and Use Committee.
Wild-type C57BL/6J mice were purchased from the National Labo-
ratory Animal Center of Taiwan. Induction of Th17 cells in vivo
was performed similarly as previously reported (Shi et al., 2013).
Briefly, LPS (100 mg; Escherichia coli 00041:B4; Sigma-Aldrich) was
injected intraperitoneally into 8- to 12-week-old mice, followed
2 hr later by transfer of hMSCs (1 3 105 cells/mouse) after non-
target or IL-25 RNAi transfection (siCtrl or siIL-25, respectively).
Mice were sacrificed on day 3 with harvesting of splenocytes for
assessment of IL-17A+ expression in CD4 T cells.
ChIP
ChIP assay was performed using the EZ-Zyme chromatin prep kit
(Millipore) and EZ-ChIP kit (Millipore), according to the manufac-
turer’s protocols. The digested chromatin was used formultiple im-
munoprecipitations with anti-STAT3 (124H6) mouse monoclonal
antibody (Cell Signaling Technology, 9139) and normal mouse
IgG. One percent of the reaction was removed as input chromatin.
PCR detection was performed using the primer sets specific for
the putative STAT3-binding sites in the human CD274 pro-
moter region. The sequences of the primer sets were forward
50-AGGTGCGTTCAGATGTTGGC-30 and reverse 50-TGCCCAAGG
CAGCAAATCCAG-30, amplifying the segment from 337 to
118 bp, and forward 50-TGACACCATCGTCTGTCATC-30 and
50-GTCAGCAGCAGACCCATATG-30, amplifying the segment
from 803 to 477 bp.
Immunoblot Analyses
Total cell lysates were prepared by lysing cells in lysis buffer
(300 mMNaCl, 50 mMHEPES [pH 7.6], 1.5 mMMgCl2, 10% glyc-
erol, 1% Triton X-100, 10 mM NaPyrPO4, 1 mM EGTA, 0.1 mM
EDTA, 1 mM DTT, 1 mM PMSF, and 1 mM Na4VO3) at 4
C for
15 min. Lysates were first clarified by centrifugation at 12,000 3 g
for 20 min. Equal amounts of samples were resolved in 7% SDS-
PAGE, followed by transferring to nitrocellulose (GE Healthcare)
and blotting with anti-IL-25R antibody (GeneTex, 97C691).
Statistical Analyses
Student’s t test (two-tailed) was performed for statistical analysis
between two groups, and ANOVA was performed for statistical an-
alyses ofmultiple groups. Statistical significancewas set at p < 0.05.
All data were expressed as mean ± SD.
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